Understanding how immune cells interact with medulloblastoma tumors
Identifying therapeutic pathways targeting medulloblastoma-immune cell interactions
This study is looking at how brain cancer cells and immune cells work together in children with medulloblastoma, hoping to find new ways to improve treatment by understanding these interactions better.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11083716 on NIH RePORTER |
What this research studies
This research investigates the interactions between tumor cells and immune cells in medulloblastoma, a type of brain cancer that primarily affects children. By employing advanced techniques such as single-cell proteomics and computational modeling, the team aims to map these interactions and their clinical implications. The study will analyze human samples and validated mouse models to identify potential therapeutic targets that could improve treatment outcomes. Patients may benefit from insights gained into how immune responses can be harnessed to fight this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma who are undergoing treatment or have recently completed treatment.
Not a fit: Patients with other types of brain tumors or those who do not have a diagnosis of medulloblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the immune response against medulloblastoma, potentially improving survival rates for affected children.
How similar studies have performed: Other research has shown promise in targeting immune cell interactions in various cancers, suggesting that this approach could be effective for medulloblastoma as well.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Fraenkel, Ernest — Massachusetts Institute of Technology
- Study coordinator: Fraenkel, Ernest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.